Preface by Linda Elsegood, Founder LDN Research Trust
Foreword by Pamela W. Smith, M.D., MPH, MS
Pharmacology and Best Clinical Practices by J. Stephen Dickson, BSC (hons) MRPharmS
Drug-Resistant Depression by Dr. Elizabeth Livengood, NMD
Virally Damaged Tissues ( including: COVID-19, Herpes Simplex (HSV 1 & 2), Varicella-Zoster, Human Parvovirus B19 (B19V), Epstein-Barr (EBV) by Sarah J. Zielsdorf, MD, MS
LDN and Longevity by Yusuf M. (JP) Saleeby, MD
Mixed Connective Tissue Disease by Deanna Windham, DO
Mold Illness and CIRS by Kent Holtorf, MD
Ophthalmic Conditions by Sebastian Denison, RPh, FAAR
Long COVID by Professor Angus G. Dalgleish, FRCP FRCPath FMedSci and Wai M. Liu, PhD
Cancer and Case Studies by Angus Dalgleish,FRCP FRCPath FMedSc Wai M. Liu, PhD and Nasha Winters, ND, FABNO
Epilogue by Yoon Hang “John” Kim, MD
APPENDIX - Dosing Protocols by Sarah J. Zielsdorf, MD, MS
SHIPPING OUTSIDE THE US AND UK
Complete this form, and we will explain how to place orders in your Country.
The LDN Book, Volume 3 is both a resource for practitioners, pharmacists and patients and a renewed call for further research on the healing potential of this generic drug.